In the rapidly evolving field of precision medicine, Antibody Conjugate Oligonucleotides (ACOs) are emerging as a promising class of therapeutics that combine the targeting precision of monoclonal antibodies with the gene-silencing power of oligonucleotides. This fusion is designed to overcome many of the delivery challenges associated with traditi

Read More